Inivata Highlights New Clinical Data on the InVision™ ctDNA Liquid Biopsy Platform in advanced NSCLC at ASCO 2017 Annual Meeting

Inivata Highlights New Clinical Data on the InVision™ ctDNA Liquid Biopsy Platform in advanced NSCLC at ASCO 2017 Annual Meeting

Study shows InVision to be more sensitive than ddPCR and detects competing resistance mutations

Inivata, a global clinical cancer genomics monitoring company employing a revolutionary approach to circulating tumor DNA (‘ctDNA’) analysis to improve personalized healthcare in oncology, today announces new clinical data, from a collaboration with Dana-Farber Cancer Institute, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

In this retrospective, blinded validation study in patients with non-small cell lung cancer (NSCLC), InVision ctDNA liquid biopsy analysis was more sensitive than droplet digital PCR (ddPCR), assessing ctDNA with high specificity and quantitative concordance. In a subset of cases, serial use of InVision was able to detect the emergence of competing resistance mutations, creating an opportunity for the study of osimertinib-based targeted therapy combinations to be monitored in patients with NSCLC.

The data will be presented by Dr Nicolas Marie Guibert from Dr Geoffrey Oxnard’s group at Dana-Farber Cancer Institute in the poster session Tumor Biology on Saturday 3 June, 13:45 – 16:45: Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib (Abstract No: 11529).

Commenting on the data, Geoffrey Oxnard, MD, thoracic oncologist and lung cancer researcher at Dana-Farber Cancer Institute, said: 

“We are excited about the potential for plasma next-generation sequencing to identify emerging resistance mutations on EGFR targeted therapy, suggesting a possible future role as a monitoring assay to help guide the treatment of resistance.”

Clive Morris, Chief Medical Officer of Inivata, said: 

“This study adds to the growing evidence supporting the excellent clinical sensitivity and specificity of our InVision ctDNA panel. Our efforts are now extending into multiple studies that will help demonstrate the clinical utility of the test in different cancer settings, including clinical monitoring.”